Inhibitor Antibody Management Therapy in Hemophilia

In human hemophilia, inhibitor antibody actually is a type of alloantibody that produced by the immune system reacting with clotting factors. The proper management of inhibitor antibody is a beneficial therapy for hemophilia treatment. Creative Biolabs is a specialist who is committed to providing comprehensive antibody products and services based on a series of advanced technology platforms.

Background of Inhibitor Antibody

Normally, in response to the invasion of exogenous substances, antibodies are produced by the immune system to eliminate or destroy these antigens to protect the body. For the patients with hemophilia, the immune system mistakes the normal clotting factors or replacement factors as antigens and produce antibodies to fight against them function properly. The produced high-affinity antibodies (IgG) under this case are defined as inhibitor antibodies (or inhibitors, also known as alloantibody).

The production of these anti-clotting factors inhibitor antibodies is a serious complication of hemophilia due to the difficulty in bleeding control and ineffectiveness of factor replacement therapy. The presence of inhibitor antibodies is a challenge to hemophilia clinical treatment, and novel therapeutic approaches and molecules are required to eliminate inhibitor antibodies.

Fig.1 Principles of the immune response to exogenous FVIII and FIX. (Astermark, 2012)

Inhibitor Antibody Management Therapy in Hemophilia

Hemophilia is a kind of rare genetic bleeding disorder characterized by a lack of sufficient clotting factors and disability to clot properly of the blood. Generally, factor VIII deficiency leads to hemophilia A, deficiency of factor IX and XI cause hemophilia B and hemophilia C, respectively. Replacement therapy that deficient factors supplementary has been the mainstay of the hemophilia treatment. The management of inhibitor antibodies to these factors is a new therapy that enables the immune system does not react with the supplemental clotting factors.

Immune tolerance therapy (ITT) or immune tolerance induction (ITI) are commonly used for inhibitor antibody management in hemophilia patients with inhibitor antibodies. Take hemophilia A as an example, the ITI can be established after frequent and regular exposure to factor VIII concentrates several months to years. Once ITI was successfully established, factor VIII replacement therapy is an effective treatment for hemophilia A patients. Additionally, humanized bispecific antibody emicizumab is an approved therapeutic antibody for with and without inhibitor antibodies.

Equipped with state-of-the-art research and manufacturing facilities, Creative Biolabs is confident in applying these inhibitor antibodies for the treatment of hemophilia. More importantly, we also offer engineering and related applications of agonistic antibody and antagonistic antibody based on the value of quality first.

Just feel free to contact us for more detailed communications and information. We are more than happy to share our experience and help our customers in related researches.

Reference

Astermark, J. Prevention and prediction of inhibitor risk. Haemophilia. 2012, Suppl 4: 38-42.

All listed services and products are For Research Use Only. Do Not use in any diagnostic or therapeutic applications.

	USA: Europe: Germany:
	Call us at: USA: UK: Germany:
	Fax:
	Email: